

## For Immediate Release

# CordLife Opens New Jakarta Cord Blood Facility

### Key Points:

- New state-of-the-art umbilical cord blood processing and storage facility opens in Jakarta
- CordLife is the only licenced cord blood banking company in Indonesia
- CordLife Indonesia – a joint venture between CordLife and Kalbe Farma
- Committed to the highest quality standards, leveraging off expertise and experience of CordLife group

30<sup>th</sup> September 2007 – Leading cord blood banking company CordLife Ltd (ASX: CBB) and Southeast Asia's largest pharmaceutical company, Kalbe Farma Tbk, today officially opened its new cord blood processing and storage facility in Jakarta, Indonesia, the first in the country. Officiating at the opening was the Indonesian Minister of Health, Dr Dr Siti Fadilah Supari.

This latest facility joins the CordLife network of facilities in the region, which today comprises Hong Kong, Singapore, and Sydney. Another facility will be open before the end of the year in Kolkata, India.

This new facility, located within the exclusive residential Jakarta suburb of Pulomas, is an advanced tissue facility, capable of storing up to 30,000 cord blood units. The facility is owned and operated by CordLife Indonesia, a joint venture between CordLife Ltd and Kalbe Farma Tbk.

In addition to the usual safeguards common to all CordLife cord blood banking facilities, such as power back-up and very strict measures to minimise sample contamination, the facility has special measures against flooding. It is located on the second floor of the building, with special purpose-built water resistant walls, and emergency pumps. The facility also has 24 hour manned security.

As with all its facilities, the new Jakarta facility conforms to the CordLife group's high quality standards in tissue processing. CordLife Singapore is the only AABB accredited facility for autologous banking in the region. BioCell Australia is TGA approved, and CordLife Hong Kong recently attained ISO 9001:2000 certification. The various quality processes learned across the network, is applied in Jakarta.

Earlier this year, CordLife announced that it has received formal notification from the Indonesian Government and its Ministry of Health of a conditional license and



approval for the company's cord blood bank, making it the only licensed and approved cord blood banking services provider in the country.

The joint venture has worked hard to demonstrate its competence and commitment to the Indonesia government and its people to secure this license. The company will now seek to work even more closely with the relevant agencies to ensure that the government's policies and quality requirements in delivering cord blood banking services are met.

"With one of the largest population base in the region, Indonesia adds five million potential new births and market size to CordLife cord blood banking business every year. Our experiences in the past years operating in Indonesia and our intimate partnership with Kalbe Farma have been key to our success in gaining a market leadership in the Indonesian market," said Mr Steven Fang, Group CEO of CordLife.

"This year, CordLife continues to expand aggressively, while still remaining very focussed on delivering the highest quality standards," Mr Fang added. "Later this year, a new facility in Singapore will be opened, with enhanced storage capacity to meet growing demand, as well as our facility in Kolkata, our first in the Indian sub-continent. In the months and years ahead, CordLife will open more facilities and marketing offices across the region, to meet the increasing demand for this potentially life-saving service."

**About CordLife**

CordLife is a leading tissue and cord blood banking company, with operations in Singapore, Australia, Hong Kong, India, Indonesia, Philippines and Thailand, and a representative office in China. CordLife holds patents in the fields of stem cell expansion and differentiation. CordLife is listed on the Australian Stock Exchange, under the symbol CBB. For more information, please visit [www.cygenics.com](http://www.cygenics.com).

**About PT Kalbe Farma Tbk**

Kalbe Farma is the largest publicly-listed pharmaceutical company in Southeast Asia, with approximately US\$1.5 billion market capitalisation and US\$600 million in revenue (2005), marketing and selling its products in 6 major markets in Southeast Asia which in aggregate represent a population of almost 500 million. Kalbe Farma focus on three business segments: consumer health (47% of revenues); prescription pharmaceuticals (23% of revenues); and distribution and packaging (30% of revenues). They have over 12,000 employees, and a sales force of 6,000 covering 80% of the Indonesian consumer health and 100% of the Indonesian prescription pharmaceutical market. For further information, please visit [www.kalbefarma.com](http://www.kalbefarma.com).

***For more information, please contact:***

Steven Fang, CEO, Cordlife Tel: +61 (0)3 9642 5580 Mob: +61 (0)400 933 243 Email: <a href="mailto:sfang@cordlife.com">sfang@cordlife.com</a>	
---	--